Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.14218/JCTH.2014.00026 http://scihub22266oqcxt.onion/10.14218/JCTH.2014.00026 C4521240!4521240!26355326     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Transl+Hepatol 2014 ; 2 (4): 285-91 Nephropedia Template TP {{tp|p=26355326|t=2014. Update on Hepatitis B Virus Infection: Focus on Treatment |pdf=|usr=}}{{26355326}} gab.com Text Update on Hepatitis B Virus Infection: Focus on Treatment JO: J Clin Transl Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=26355326 #FOAvip This review article is an update of the current treatment strategies available for chronic hepatitis B. In addition to achieving on-therapy clinical remission and suppression of HBV replication without resistance, the ultimate goal of therapy is the development of sustained remission and HBsAg loss after discontinuation of treatment. This is the closest possible to cure outcome for hepatitis B virus (HBV) infection. These goals can be achieved by response-guided courses of pegylated interferon (peg-IFN)-alpha at rates higher than 30%, both in hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients. Review of the data regarding discontinuation of long term NA treatment in HBeAg-negative patients revealed that stopping such therapy is safe with high rates of sustained off treatment responses that appear to be immunologically induced. Decreasing hepatitis B surface antigen (HBsAg) titers under therapy to <500, particularly <100 IU/mL, and adding a course of peg-IFN to ongoing long term nucleos(t)ide analogue (NA) therapy increase the percentage of sustained responses following discontinuation of NA treatment. Twit Text FOAVip Update on Hepatitis B Virus Infection: Focus on Treatment ????J Clin Transl Hepatol http://www.kidney.de/pget.php?&tw=1&pmid=26355326 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26355326 #FOAvip English Wikipedia <ref>{{Cite pmid|26355326}}</ref> Update on Hepatitis B Virus Infection: Focus on Treatment #MMPMID26355326 Hadziyannis SJ J Clin Transl Hepatol 2014[Dec]; 2 (4): 285-91 PMID26355326show ga This review article is an update of the current treatment strategies available for chronic hepatitis B. In addition to achieving on-therapy clinical remission and suppression of HBV replication without resistance, the ultimate goal of therapy is the development of sustained remission and HBsAg loss after discontinuation of treatment. This is the closest possible to cure outcome for hepatitis B virus (HBV) infection. These goals can be achieved by response-guided courses of pegylated interferon (peg-IFN)-alpha at rates higher than 30%, both in hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients. Review of the data regarding discontinuation of long term NA treatment in HBeAg-negative patients revealed that stopping such therapy is safe with high rates of sustained off treatment responses that appear to be immunologically induced. Decreasing hepatitis B surface antigen (HBsAg) titers under therapy to <500, particularly <100 IU/mL, and adding a course of peg-IFN to ongoing long term nucleos(t)ide analogue (NA) therapy increase the percentage of sustained responses following discontinuation of NA treatment. äUpdate on Hepatitis B Virus Infection: Focus on Treatment (epmc).pdf DeepDyve Pubget Overpricing